Numerous studies provide evidence that Src inhibitors are effective in reducing proliferation and invasion of prostate cancer cell lines in vitro and demonstrate favorable antitumor activity in vivo using prostate cancer xenografts (38–40). This evidence concerns the gene SRC and prostate cancer.